These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 3771819)

  • 1. Tardive dyskinesia in outpatient schizophrenics treated with depot phenothiazines.
    Williams R; Naya A; Dalby JT
    J Clin Psychopharmacol; 1986 Oct; 6(5):318-9. PubMed ID: 3771819
    [No Abstract]   [Full Text] [Related]  

  • 2. Tardive dyskinesia in schizophrenic outpatients: prevalence and significant variables.
    Ezrin-Waters C; Seeman MV; Seeman P
    J Clin Psychiatry; 1981 Jan; 42(1):16-22. PubMed ID: 6109715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tardive dyskinesia following low doses of piperacetazine.
    Dominguez RA
    Am J Psychiatry; 1980 Dec; 137(12):1617. PubMed ID: 6108083
    [No Abstract]   [Full Text] [Related]  

  • 4. An effective palliative treatment for phenothiazine-induced tardive dyskinesia.
    Betts WC; Johnston FS; Pratt MJ
    N C Med J; 1979 May; 40(5):286. PubMed ID: 86958
    [No Abstract]   [Full Text] [Related]  

  • 5. Depot pipotiazine 1970-1982: a review.
    Burch EA; Ayd FJ
    J Clin Psychiatry; 1983 Jul; 44(7):242-7. PubMed ID: 6134718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of attention/information processing impairment of tardive dyskinesia and neuroleptics in chronic schizophrenics.
    Spohn HE; Coyne L
    Brain Cogn; 1993 Sep; 23(1):28-39. PubMed ID: 8105820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of drug withdrawal on tardive dyskinesia.
    Crane GE; Ruiz P; Kernohan WJ; Wilson W; Royalty N
    Act Nerv Super (Praha); 1969; 11(1):30-5. PubMed ID: 5770140
    [No Abstract]   [Full Text] [Related]  

  • 8. The effects of a drug holiday on relapse and tardive dyskinesia in chronic schizophrenics [proceedings].
    Goldberg SC; Shenoy RS; Sadler A; Hamer R; Ross B
    Psychopharmacol Bull; 1981 Jan; 17(1):116-7. PubMed ID: 7232638
    [No Abstract]   [Full Text] [Related]  

  • 9. Administration of butaperazine and plasma methionine-enkephalin levels in schizophrenic and affective disorder patients with tardive dyskinesia.
    Mosnaim AD; Wolf ME
    J Clin Psychopharmacol; 1988 Aug; 8(4 Suppl):27S-30S. PubMed ID: 2906066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of the incidence of tardive dyskinesias in 3 groups of patients treated with different neuroleptics].
    Barcia D; Pozo P; Ruiz ME; Forcadell F; Morcillo L; Soria JM; Carrasco E
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1987; 15(1):25-8. PubMed ID: 3577874
    [No Abstract]   [Full Text] [Related]  

  • 11. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders.
    Ganzini L; Casey DE; Hoffman WF; McCall AL
    Arch Intern Med; 1993 Jun; 153(12):1469-75. PubMed ID: 8512437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does clozapine cause tardive dyskinesia?
    Kane JM; Woerner MG; Pollack S; Safferman AZ; Lieberman JA
    J Clin Psychiatry; 1993 Sep; 54(9):327-30. PubMed ID: 8104929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High neuroleptic plasma levels in patients manifesting supersensitivity psychosis.
    Chouinard G; Creese I; Boisvert D; Annable L; Bradwejn J; Jones B
    Biol Psychiatry; 1982 Jul; 17(7):849-52. PubMed ID: 7115836
    [No Abstract]   [Full Text] [Related]  

  • 14. Tardive dyskinesia in chronic schizophrenic inpatients.
    Kua EH; Ang PC; Siew HC
    Singapore Med J; 1982 Feb; 23(1):19-21. PubMed ID: 6126008
    [No Abstract]   [Full Text] [Related]  

  • 15. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study.
    Levine J; Schooler NR; Severe J; Escobar J; Gelenberg A; Mandel M; Sovner R; Steinbook R
    Adv Biochem Psychopharmacol; 1980; 24():483-93. PubMed ID: 6996445
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of gradual decrease and discontinuation of neuroleptics on clinical condition and tardive dyskinesia [proceedings].
    Branchey MH; Branehey LB; Richardson MA
    Psychopharmacol Bull; 1981 Jan; 17(1):118-20. PubMed ID: 7232639
    [No Abstract]   [Full Text] [Related]  

  • 17. Preliminary findings with regard to risk factors in the development of tardive dyskinesia [proceedings].
    Kane J; Struve F; Woerner M; Weinhold P
    Psychopharmacol Bull; 1981 Jan; 17(1):47-9. PubMed ID: 6112775
    [No Abstract]   [Full Text] [Related]  

  • 18. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study.
    Miyaoka T; Furuya M; Yasuda H; Hayashida M; Nishida A; Inagaki T; Horiguchi J
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):761-4. PubMed ID: 18201810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tardive dyskinesia and impaired glucose tolerance.
    Chong SA; Mythily ; Lum A; Huak CY; Kane J
    Hum Psychopharmacol; 2002 Aug; 17(6):305-7. PubMed ID: 12404676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence.
    Kane JM
    J Clin Psychiatry; 2004; 65 Suppl 9():16-20. PubMed ID: 15189107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.